MoonLake Immunotherapeutics (MLTX) Non-Current Deffered Revenue (2020 - 2022)

MoonLake Immunotherapeutics' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $4.0 million for Q1 2022.

• In Q1 2022, Non-Current Deffered Revenue changed 0.0% year-over-year to $4.0 million; the TTM figure through Mar 2022 stood at $4.0 million (changed 0.0% YoY), while the FY2021 annual figure was $4.0 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue was $4.0 million for Q1 2022 at MoonLake Immunotherapeutics, roughly flat from $4.0 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $4.0 million in Q4 2020 to a low of $4.0 million in Q4 2020.
• Historically, Non-Current Deffered Revenue has averaged $4.0 million across 3 years, with a median of $4.0 million in 2020.
• Biggest YoY gain for Non-Current Deffered Revenue was 0.0% in 2021; the steepest drop was 0.0% in 2021.
• A 3-year view of Non-Current Deffered Revenue shows it stood at $4.0 million in 2020, then changed by 0.0% to $4.0 million in 2021, then changed by 0.0% to $4.0 million in 2022.
• The last three Non-Current Deffered Revenue figures came in at $4.0 million (Q1 2022), $4.0 million (Q4 2021), and $4.0 million (Q3 2021), per Business Quant data.